SensiPhi® (formerly QualiPhi®) is an improved version of the wild-type Phi29 DNA polymerase with enhanced affinity for DNA. SensiPhi® strongly increases the efficiency of the amplification of small amounts of DNA over the wild type. This has been achieved by engineering the wild-type form of the enzyme as detailed in a scientific publication that has appeared in the renowned scientific journal PNAS. More information here.
These unique features will make SensiPhi® the new standard for isothermal DNA amplification.
SensiPhi® has been licensed for DNA amplification exclusively to QIAGEN, the world leading supplier of sample and assay technologies. QIAGEN is one of the leaders in this field and commercializes kits for amplification of DNA / RNA with this enhanced enzyme under the name SensiPhi® since February 2014.
SensiPhi® is protected by a US patent issued 2013, further patents are pending. SensiPhi® advantages over the wild type of Phi29 polymerase
- Improved DNA binding
- Enhanced rolling circle amplification (RCA) efficiency
- Enhanced whole genome multiple displacement amplification (MDA)
- Reduced standard reaction times (e.g. from 8 hours to 2 hours)
- Significant reduction in starting material needed
Novel QualiPhi® Mutants
QualiPhi®, a superior version of phi29 DNA polymerase has been licensed to QIAGEN, and will there be exclusively used for amplifications of nucleic acids. However, phi29-type DNA polymerases also have great potential for sequencing applications due to their excellent fidelity and extremely high processivity. Indeed, a number of next generation sequencing companies already use Phi29 DNA polymerase in their platform. There is a considerable market need for improved sequencing enzymes due to frequent problems with reading lengths and error rates in today’s sequencing technologies.
SYGNIS is developing novel sequencing variants of Qualiphi® that take advantage of the improved properties of QualiPhi® and in addition incorporate novel features for optimization of sequencing performance. Such desirable features include for example reduced or absent exonuclease activity or improved handling of modified nucleotides by the enzyme. In designing such novel features SYGNIS draws from the vast advisor and internal scientific expertise in DNA polymerases SYGNIS aims to advance this exciting project in a co-development agreement with a NGS technology provider or a service company.